Hanson Wade

R&D

Partner Content

13th HPAPI: Process Development for Highly Potent Drugs

The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and

R&D

Partner Content

3rd In Vivo Cell Engineering & Gene Editing Summit

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

R&D

Partner Content

6th Cell Engager Therapeutics Summit 2024

Advancing the Development of Novel Targets, Safe, & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic

R&D

Partner Content

4th mRNA-Based Therapeutics Summit

Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to Commercialisation by Ensuring Targeted Delivery, Durability & Tolerable Immunogenicity Across All Disease Indica

R&D